Roche has priced its cancer treatment Rozlytrek at $17,050 per month, about half the cost of a similar drug sold by Eli Lilly and Bayer, according to STAT.
Rozlytrek, approved Aug. 15, targets solid tumors that show rare genetic defects called NTRK gene fusions and ROS1-positive non-small cell lung cancer.
Eli Lilly and Bayer's drug Vitrakvi is priced at $32,800 per month. It also treats tumors with NTRK gene fusions.